Novoflow is building AI employees that automate medical operations for clinics. Novoflow built the universal bridge into EHR systems—so every workflow, from scheduling to billing, can finally run on AI. The first product is an AI employee that talks to patients and uses computer agents to book, reschedule, and recover cancelled appointments. Built for healthcare providers and hospitals.

We help oncologists and radiologists extract insights from CT scans to support tumor characterization and treatment. The hospitals we work with include Stanford Hospital, Cedars-Sinai (the largest hospital in California), UCI Health, and Weill Cornell.

Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge machine learning algorithms. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.

Obento Health is redefining the CRM experience for medical field sales. Designed specifically for healthcare, we are saving reps time from documentation and empowering reps to create more personalized interactions with their customers.

Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.

Okani is a low-cost wellness membership for the 50M Mexicans that spend 25B on healthcare out of pocket. We become patients' first point of contact with the healthcare system by providing digital primary care through chat and an app, then orchestrate the delivery of secondary healthcare with physicians, labs, pharmacies and clinics. We're founded by a team of 3 engineers and a doctor with a masters in clinical care. Pepe previously sold a startup to Cabify and ran engineering with Romario for Nubank's first international market.

Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.

We are building the technical infrastructure to train and pay the 53M family caregivers in the US.

Oncobox believes that many late-stage cancer patients are dying prematurely because doctors lack a data-driven tool to help them decide which drugs currently on the market would most effectively fight individual patients’ specific cancers. That’s where Oncobox comes in. Oncobox is low-cost personalized genetic profiling to help doctors decide which drug to use. In a recent study conducted by leading cancer researchers in Europe and Asia on 900 patients with various late-stage cancers, Oncobox increased the effectiveness of targeted therapies from 25% to 64%. How does Oncobox work? Over 150 targeted cancer drugs are currently on the market. But deciding which of these drugs to give to late-stage cancer patients is not a simple task. Cancer doctors are in a race against the clock. They don’t always know which medication will be most effective for their patients. Because these drugs are expensive and typically have significant side effects, they can’t just try them all. Because of these barriers, targeted cancer therapies are effective only 25% of the time, and 70% of patients with late-stage cancers die due to the toxic side effects of ineffective drugs. Oncobox Dx analyses tumor DNA, RNA, and molecular pathways using algorithms to distinguish which molecular targets are the most crucial for individual cases. Doctors receive a clinically actionable report that shows them which drugs are likely to be most effective on the patient. We actively seek partners from pharma, hospitals/clinicians, payers, and genomic centers. Feel free to contact us at hello@oncobox.com. Our team and the scientific advisory board consisting of leading scientists and researchers from UCLA, Stanford, Johns Hopkins University, Boston University, Tufts University, and Rutgers University.

One Codex is a data platform for applied microbial genomics, enabling new and valuable applications in clinical diagnostics, food safety, and biosecurity. Acquired by Invitae (NVTA) in February 2021. Spun out as an independent company in September 2022.

We are a nonprofit stool bank, expanding safe access to fecal transplants and catalyzing research on the human microbiome.

Today, biologists spend too much time pipetting by hand. We think biologists should have robots to do pipetting for them. People doing science should be free of tedious benchwork and repetitive stress injuries. They should be able to spend their time designing experiments and analyzing data. That's why we started Opentrons. We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other's results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century’s most important questions.

Ophelia helps people quit opioids without going to rehab. We offer online doctor’s visits, withdrawal medication prescriptions, and support for long-term recovery, using a protocol 6x more effective than most rehabs (2/3rds of which don't have doctors). More than 3 million Americans are addicted to opioids, but 80% are not getting help, due to jobs, families, and privacy concerns. Meanwhile, there's a proven treatment that increases survival rates by 600%, and it's low cost, discreet, and convenient. It's called MAT, and it looks like treatment for anxiety or depression: medication plus therapy. However, doctors need a special waiver to prescribe the medication, which fewer than 5% of them have, so it's difficult to get, and most people are buying it on the street. Sadly, drug dealers aren't doctors: every 11 minutes another American dies of an opioid overdose, now the #1 cause of death for Americans under 50. Ophelia is replacing rehab with telemedicine, using proven science and a consumer-first approach. The opioid treatment market in the U.S. is $15B, and 85% of opioid addicts have insurance that pays for it. We're treating roughly 400 patients with thousands more waiting. Zack started Ophelia after losing his girlfriend to an opioid overdose, who found it easier to get medication from a drug dealer than a doctor. We are raising money to help patients in waiting, grow our footprint, save lives, and earn venture-level returns for investors.

Opkit uses AI to automate routine phone calls for medical practices, telehealth companies, and other leading healthcare provider organizations. Opkit's AI agent is capable of executing a wide-range of non-clinical phone call tasks, including Verification of Benefits, patient intake, and appointment scheduling, without human intervention. Opkit is HIPAA-compliant and SOC 2 Type 2 certified.

Orange Health Labs is India’s leading on-demand diagnostics lab for urban consumers, offering 30-minute at-home sample collection and 6 hour reports across the top cities of India Launched in January 2021, Orange Health Labs is amongst the most loved healthcare brands in India and is backed by some of the world’s leading investors like Accel, General Catalyst, Y Combinator, Bertelsmann India, Amazon, and others.

Orchid is an AI-powered Electronic Health Record (EHR) for independent mental health professionals that saves them time, money, and frustration by integrating core administrative workflows, streamlining clinical processes, and automating manual flows.

Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified small molecules that reduce the toxic mutated protein, suppress mutant protein-induced toxicities in human disease neurons and get into the brain. We anticipate that this approach will be broadly applicable to traditionally “undruggable” targets in other neurological diseases.

Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science. The Osmind treatment platform is the first and only solution that solves specific challenges faced by neuropsychiatric clinics, spanning general psychiatry and interventional psychiatry (transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, electroconvulsive therapy). The core electronic health record (EHR) technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients. Research from our platform is already helping to set new standards for mental health interventions. For example, in the largest published real-world analysis of ketamine infusion therapy for depression, we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022). We have multiple ongoing research studies leveraging our proprietary real-world data, including an even larger ketamine analysis leveraging machine learning to predict treatment outcomes. Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.

Oto’s digital programs are the best way to manage tinnitus, and at a fraction of the cost of in person treatment. Tinnitus or ringing in the ears affects 1 in 8 people, and before Oto effective therapy was only available via expensive meetings with a specialist.

Output Biosciences is pioneering Biologically-Aware Generative AI to finally understand complex biological systems. Our new generative AI architecture can handle the extremely long, nonlinear, fragmented, and high dimensional data of biological systems. We are building Large Biological Models that can generate breakthrough medicines and transform the way we diagnose, treat and prevent disease.

Overdrive Health offers AI powered medical billing services, helping providers get paid more money in less time. Our technology enables us to provide the best quality insurance and patient billing services for a fraction of the usual cost

PNOĒ enables health professionals to provide science-backed bio-optimization through breath analysis. For 100+ years, breath analysis (AKA metabolic testing, VO2max) has been the gold standard in anti-aging quantification, nutrition prescription, and evaluation of most critical systems, including the heart, lungs, cells, and nervous system. Until recently, it was only available in sophisticated clinics and regarded as the most valuable but underutilized assessment in medicine. PNOĒ changed that through the first easy-to-use clinical-grade breath analysis device, proprietary software package, and dedicated metabolic expert support. Through a non-invasive 10 min breath test, PNOĒ analyzes the human breath and prescribes a personalized nutrition, exercise, breathwork, and bio-optimization (i.e., red light therapy, hyperbaric chamber, IV therapy, etc.) program based on one’s biological limitations. 3,000+ health professionals trust PNOĒ because it personalizes the clients’ journey through their clinics, builds retention by quantifying progress, and enables the upsell of personalized nutrition and breathwork. All this without any effort, time commitment, or upfront cost. PNOĒ has been independently validated by Georgetown University, VA in Maryland, and Rutgers University and is trusted by leading institutions including Cenegenics, Dais Cove, MIT, UCLA, Pan Pacific, CLMBR, UCS, OURA, TONAL, Spartan Racing, and Paris Saint Germain.

Pair Team cares for the highest-need Medicaid recipients through a community-led, virtual care model. We take responsibility for the whole person by addressing not just clinical needs, but also health-related social needs such as housing instability and food access. We partner with local community-based organizations like shelters and safety net providers to coordinate care alongside our multidisciplinary care team to improve the wellbeing of underserved individuals and communities.